Multiple Treatments for Non-Small Cell Lung Cancer
(ALTAIR Trial)
Trial Summary
What is the purpose of this trial?
The purpose of this study is to assess the safety and efficacy of multiple study interventions including novel-novel combinations or novel agents in combination with standard therapy for the treatment of metastatic NSCLC.
Eligibility Criteria
This trial is for individuals with advanced non-small cell lung cancer (NSCLC). Participants should be adults who can provide informed consent and are eligible to receive chemotherapy. Specific criteria may vary, so it's important to consult the study team for details.Inclusion Criteria
Exclusion Criteria
Treatment Details
Interventions
- AB248
- Cisplatin
- Nab-paclitaxel
- Pemetrexed
- Rilvegostomig
Find a Clinic Near You
Who Is Running the Clinical Trial?
AstraZeneca
Lead Sponsor
Sir Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris
Dr. Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology
Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris
Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Medical Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology